Skip to main content
Equasens logo

Equasens — Investor Relations & Filings

Ticker · EQS ISIN · FR0012882389 LEI · 96950066I7XVFGZI8L92 PA Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 326 across all filing types
Latest filing 2021-08-04 Earnings Release
Country FR France
Listing PA EQS

About Equasens

https://equasens.com

Equasens is a company specializing in healthcare IT solutions for professionals and establishments. It develops and provides a range of products including professional software, electronic equipment, connected devices, and digital health solutions. The company's offerings cater to a diverse client base, including pharmacies, hospitals, nursing homes (EHPADs), home care services, and independent medical practitioners. The primary objective of its solutions is to improve the quality of patient care by facilitating the secure sharing of health data, enhancing communication between different care providers, and optimizing the coordination of care pathways across outpatient, hospital, and home care settings.

Recent filings

Filing Released Lang Actions
Pharmagest Interactive: H1 2021 sales: +20.49% to €93.90m
Earnings Release Classification · 1% confidence The document is a press release titled 'H1 2021 sales' which provides a summary of revenue performance, business highlights, and growth targets for the first half of 2021. It explicitly states that the full H1 results will be published on 24 September 2021, indicating that this document is an initial announcement of financial highlights rather than the full interim report itself. Therefore, it is classified as an Earnings Release. H1 2021
2021-08-04 English
PHARMAGEST INTERACTIVE : Chiffre d’affaires du 1er semestre 2021 : +20,49% à 93,90 M€
Earnings Release Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and focuses on the "Chiffre d'affaires du 1er semestre 2021" (First Half 2021 Revenue). It provides key financial highlights, divisional performance breakdowns, and confirms future growth ambitions for 2021. This structure—a summary announcement of period results—is characteristic of an Earnings Release (ER). Although it covers a half-year period (which might suggest an Interim Report (IR)), the format is a concise press release summarizing the figures rather than the comprehensive, detailed financial statements typically found in a full Interim Report. Furthermore, the document explicitly lists the 'Publication des résultats semestriels' (Publication of half-year results) scheduled for September 24, 2021, indicating this document is the preliminary announcement of those results, fitting the definition of an Earnings Release (ER). H1 2021
2021-08-04 French
Pharmagest Interactive: H1 2021 HALF-YEAR REPORT ON THE LIQUIDITY AGREEMENT WITH GILBERT DUPONT
Capital/Financing Update Classification · 1% confidence The document is explicitly titled "H1 2021 HALF-YEAR REPORT ON THE LIQUIDITY AGREEMENT WITH THE BROKERAGE FIRM GILBERT DUPONT". It provides detailed financial figures (shares, cash balance, purchases, sales) for the first half (H1) of 2021, comparing them to the previous year-end (31 December 2020). The term 'HALF-YEAR REPORT' strongly indicates a comprehensive report covering a period shorter than a full year. This aligns directly with the definition of an Interim / Quarterly Report (IR), even though the content is specific to a liquidity agreement rather than the entire company's operations, as it summarizes performance over an interim period (H1 2021). It is not a general Earnings Release (ER) as it is detailed and covers a half-year, not just the immediate period's results announcement.
2021-07-21 English
PHARMAGEST INTERACTIVE : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE CONTRACTE AVEC LA SOCIETE DE BOURSE GILBERT DUPONT
Capital/Financing Update Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and specifically concerns the "BILAN SEMESTRIEL S1-2021 DU CONTRAT DE LIQUIDITE" (Semi-annual Balance Sheet S1-2021 of the Liquidity Contract) for the period ending June 30, 2021. This document reports on the activity (purchases and sales of shares) under a liquidity contract, which is a specific type of financial arrangement often disclosed periodically. While it contains financial data, its primary purpose is a periodic disclosure related to market operations and compliance, rather than a full financial report (10-K or IR). It is a periodic report covering a period shorter than a year (Interim Report, S1-2021). However, the content is highly specific to the liquidity contract activity, which is a form of capital/financing activity disclosure, but the structure strongly suggests a required periodic update. Given the options, the most fitting category for a comprehensive, periodic financial update shorter than a year is the Interim Report (IR). If it were purely an announcement *about* the report, RPA would apply, but this document contains the substance of the semi-annual balance sheet itself. The reference to the AMF decision (French regulator) confirms its regulatory nature. Since it is a semi-annual report, 'IR' (Interim Report) is the best fit over general 'RNS' or specific 'CAP'.
2021-07-21 French
Pharmagest Interactive: ORDINARY ANNUAL SHAREHOLDERS' MEETING OF 29 JUNE 2021 - RESULTS OF THE VOTES
AGM Information Classification · 1% confidence The document explicitly details the 'RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED TO THE ORDINARY ANNUAL SHAREHOLDERS' MEETING OF 29 JUNE 2021'. It lists numerous resolutions voted upon, including the approval of financial statements, discharge of directors, renewal of director terms, and approval of compensation policies. This content is the official record of voting outcomes from a general meeting, which directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). It is not the AGM presentation (AGM-R), nor is it a general proxy solicitation (PSI), but the final results thereof.
2021-07-05 English
PHARMAGEST INTERACTIVE : AGO du 29 juin 2021 - Résultat du vote des résolutions
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "RESULTAT DU VOTE DES RESOLUTIONS PRESENTEES A L'ASSEMBLEE GENERALE ORDINAIRE ANNUELLE DU 29 JUIN 2021" (Results of the Vote on Resolutions Presented at the Annual Ordinary General Meeting of June 29, 2021). It explicitly details the voting outcomes for numerous resolutions, including the approval of accounts, dividend allocation, renewal of director mandates, and remuneration policies, which are standard items voted upon at an AGM. This content directly corresponds to the official results of a shareholder vote following a general meeting. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2021-07-05 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.